SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Larry Liebman who wrote (991)6/20/1999 9:41:00 PM
From: Biomaven  Read Replies (1) of 1073
 
Larry,

Re SUPG:

I still own some shares that have done nicely. I think Nipent use will expand considerably and I think RFS 2000 will likely be approved and become at least moderately successful. There are some negatives, though. They are not what I would term conservative in presenting their data. For example, they have presented results (both in PR and in abstracts) using only "evaluable patients" and you have to read the fine print to see how the drug is really doing. My other concern is that they have this deal with an undisclosed bank to sell common at a reasonable discount. I don't object to the terms at all, but they have gone (far) out of their way to never disclose the name of the bank, which I find a little irksome and a little weird.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News